Vitamin D Status in Patients With Severe Sepsis

Withdrawn before enrolling · Phase 3 · Has a placebo group

Conditions studied: Sepsis, Severe Sepsis, End Organ Damage, Multi Organ Failure

In brief

Sepsis is a clinical entity that complicates infection. Without early recognition and timely management, it can rapidly progress to severe sepsis, septic shock, and culminate in multiple organ dysfunction syndrome. Forty to 70% of septic patients have low vitamin D status, yet little is known about the impact of vitamin D3 (vitD3) supplementation in this patient population. As such, the investigators propose a randomized, double-blinded, placebo-controlled trial to test the hypothesis that early, rapid correction of low vitamin D status, as an adjunct to established treatment guidelines, will improve clinical outcomes and measurably alter immune profile in patients with severe sepsis.

Key facts

Study ID
NCT02684487
Run by
Massachusetts General Hospital
People needed
0
Starts
2017-12-01
Expected to finish
2022-12-01
Last updated by the study team
2021-05-05

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.